Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SERUM M3 M21 IN OVARIAN-CANCER PATIENTS
Autore:
TEMPFER C; HEFLER L; HAEUSLER G; SLIUTZ G; HANZAL E; REINTHALLER A; KAINZ CH;
Indirizzi:
UNIV VIENNA,SCH MED,DEPT GYNAECOL & OBSTET,WAHRINGER GURTEL 18-20 A-1090 VIENNA AUSTRIA
Titolo Testata:
British Journal of Cancer
fascicolo: 10, volume: 76, anno: 1997,
pagine: 1387 - 1389
SICI:
0007-0920(1997)76:10<1387:SMMIOP>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
TISSUE POLYPEPTIDE ANTIGEN; CYTOKERATIN ASSAYS;
Keywords:
TUMOR MARKER; M3/M21; OVARIAN CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
8
Recensione:
Indirizzi per estratti:
Citazione:
C. Tempfer et al., "SERUM M3 M21 IN OVARIAN-CANCER PATIENTS", British Journal of Cancer, 76(10), 1997, pp. 1387-1389

Abstract

Cytokeratins are polypeptides that constitute a subclass of intermediate filaments in epithelial cells, The aim of the present study was toevaluate the clinical usefulness of the serum evaluation of M3/M21 inpatients with ovarian cancer, This retrospective study comprises 75 patients suffering from ovarian cancer FIGO stages la-lll, M3/M21 reached a sensitivity of 78%, a specificity of 85%, a PPV of 89% and a NPV of 83% using a cut-off level of 45 U 1(-1). Forty-four women developedrecurrent disease after complete remission during the observation period. M3/M21 showed lead time effects in 19 patients, ranging from 2 to8 months (median 3.2 months). Elevated M3/M21 serum levels before therapy were associated with a poor overall survival (log-rank test, P = 0.02). Considering these preliminary results, the value of M3/M21 as aserum tumour marker, i.e. to evaluate the tumour burden, seems promising.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 10:47:51